Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer

Published:2016-08 Issue:4 Volume:16 Page:284-290
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Wilson Sheridan,Speers Caroline,Tyldesley Scott,Chia Stephen,Kennecke Hagen,Ellard Susan^ORCID,Lohrisch Caroline

Funder

Astra Zeneca

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials;Lancet,2005

2. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials;Davies;Lancet,2011

3. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial;Fisher;J Natl Cancer Inst,2001

4. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO (“nolvadex”) trial;Singh;Br J Cancer,1988

5. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer;Br J Cancer,1988

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring?;The Journal of Liquid Biopsy;2024-03

2. Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score;Journal of Magnetic Resonance Imaging;2017-06-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3